News Janssen's Imbruvica runs into trouble with NICE in mantle ce... NICE suggests interim CDF funding while further data is gathered.
News After a year's delay, BMS seals Opdivo lung cancer deal with... Bristol-Myers Squibb will now challenge its rival, MSD's Keytruda, in second line lung cancer treatment in England after it agreed a 'managed access' deal with NICE.
News NICE close to clearing Cancer Drugs Fund backlog Only five drugs left to assess from old scheme.
News Roche hails 4 year NICE access deal for Gazyvaro NICE has agreed a deal with Roche on its new follicular lymphoma treatment Gazyvaro, giving the dru
Views & Analysis UK funding of cancer drugs: right, wrong, or just plain conf... How do the countries of the UK fund cancer drugs today, and do they have the right approaches?
News Lilly’s sarcoma drug Lartruvo recommended via Cancer Drugs F... Lilly's drug will be re-appraised in 2020
News Novo sues Lilly over 'misleading' GLP-1 ad campaigning The rivalry between Novo Nordisk and Eli Lilly in the GLP-1 market has spilled over into the courts in the US, with claims of misleading advertising.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
